Demand for nanoparticles in the biopharmaceutical industry is on the rise. Production of these tiny particles, which can protect and deliver medicines and vaccines where they need to go in the body, has been increasing since 1989. Over the last two decades, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved nearly 80 products involving nanoparticles, according to a 2022 report in Pharmaceutics. BCC research estimates that the global market for nanoparticles in biotechnology, drug development and drug delivery will reach $123.6 billion by 2025, up from $83.4 billion in 2020.
